Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) Revenue (2016 - 2025)

Historic Revenue for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q4 2025 value amounting to $18.6 million.

  • Enanta Pharmaceuticals' Revenue rose 976.47% to $18.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $67.0 million, marking a year-over-year increase of 58.42%. This contributed to the annual value of $65.3 million for FY2025, which is 341.69% down from last year.
  • Latest data reveals that Enanta Pharmaceuticals reported Revenue of $18.6 million as of Q4 2025, which was up 976.47% from $15.1 million recorded in Q3 2025.
  • Enanta Pharmaceuticals' 5-year Revenue high stood at $27.6 million for Q4 2021, and its period low was $14.6 million during Q3 2024.
  • For the 5-year period, Enanta Pharmaceuticals' Revenue averaged around $19.1 million, with its median value being $18.7 million (2022).
  • Within the past 5 years, the most significant YoY rise in Enanta Pharmaceuticals' Revenue was 1592.77% (2021), while the steepest drop was 2710.82% (2021).
  • Over the past 5 years, Enanta Pharmaceuticals' Revenue (Quarter) stood at $27.6 million in 2021, then fell by 14.7% to $23.6 million in 2022, then dropped by 23.67% to $18.0 million in 2023, then fell by 5.8% to $17.0 million in 2024, then increased by 9.76% to $18.6 million in 2025.
  • Its Revenue was $18.6 million in Q4 2025, compared to $15.1 million in Q3 2025 and $18.3 million in Q2 2025.